AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34239102
Drug: Guidelines for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines for sample preparation, replication and randomization, quantification, recovery and recombination, ion suppression and peak misidentification
Trial: 32517393
Drug: Dexmedetomidine-bupivacaine (DB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-bupivacaine (DB) group (n = 40) - 30 mL bupivacaine 0.25% plus 1 mu g/kg dexmedetomidine
Trial: 32517393
Drug: Bupivacaine (B)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine (B) group (n = 40) - 30 mL bupivacaine 0.25% only
Trial: 33211886
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (3 g/day)
Trial: 33211886
Drug: Citrate mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate mixture (7 g/day)
Trial: 36249246
Drug: Weekly SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS intervention for improving feeding practices
Trial: 33919722
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL extra-virgin olive oil supplement
Trial: 36088325
Drug: Tea and
RxNorm normalized name: Clenia Plus Green Tea and Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea and coffee (Staining agents)
Trial: 36088325
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (Staining agent)
Trial: 35933278
Drug: 1-week PrEP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week PrEP with human diploid cell culture rabies vaccine (HDCV) IM (Group 1)
Trial: 35933278
Drug: 3-week PrEP
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week PrEP with human diploid cell culture rabies vaccine (HDCV) IM (Group 2)
Trial: 35933278
Drug: 1-week PrEP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week PrEP with Vero cell rabies vaccine (PVRV) IM (Group 4)
Trial: 35933278
Drug: 1-week PrEP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week PrEP with Vero cell rabies vaccine (PVRV) ID (Group 5)
Trial: 35669363
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic drugs or diet control, appropriate exercise
Trial: 35963558
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (d-methylphenidate + guanfacine)
Trial: 35368384
Drug: Ruxolitinib 5
RxNorm normalized name: ruxolitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg twice per day
Trial: 33019874
Drug: Antibody-based therapies
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-based therapies (PEMs from BCC)
Trial: 33019874
Drug: Small molecule-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule-based therapies (PEMs from BCC)
Trial: 36181554
Drug: Digital therapeutic
RxNorm normalized name: digital therapeutics, amblyopia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital therapeutic app delivering cognitive behavioral therapy (BT‐001)
Trial: 32672489
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib (IM) and hydroxyurea (HU) combination therapy
Trial: 32672489
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib (IM) monotherapy
Trial: 36435838
Drug: Tailored lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored lifestyle and intensively supplemented with oral nutrition support (Group SS)
Trial: 33826038
Drug: Adapted Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Cognitive Behavioral Therapy (CBT)
Trial: 36121664
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with a history of digital rectal examination or PSA testing
Trial: 32730026
Drug: Self-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intervention
Trial: 32730026
Drug: Self-administered plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered plus telephone intervention
Trial: 34412668
Drug: α1-adrenergic blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: α1-adrenergic blocker (doxazosin 0.05 mg/kg)
Trial: 33769117
Drug: Fingolimod (0.5–1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (0.5–1.25 mg/day)
Trial: 35276329
Drug: 130 mg
RxNorm normalized name: pectin 130 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 mg ustekinumab
Trial: 35276329
Drug: approximately 6
RxNorm normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: approximately 6 mg/kg ustekinumab
Trial: 34799501
Drug: Dexamethasone 12
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 12 mg
Trial: 34117162
Drug: modified directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified directly administered ART (mDAART) plus standard of care
Trial: 33958719
Drug: Bovine milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk-based infant formula with 7.2 g MOS/L
Trial: 34113435
Drug: Modular intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modular intervention to improve paternal involvement in infant and young child feeding (IYCF); implemented through monthly visits for six months.
Trial: 32423247
Drug: Intranasal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroids (Nasacort)
Trial: 32423247
Drug: Placebo (Ayr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Ayr saline spray)
Trial: 35505251
Drug: HDACi anti-epileptic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDACi anti-epileptic drugs (AEDs)
Trial: 35505251
Drug: Other anti-epileptic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other anti-epileptic drugs (AEDs)
Trial: 38436495
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone (4 mg)
Trial: 33008451
Drug: Dexmedetomidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.8 μg/kg administered for 10 min before anesthesia)
Trial: 33720960
Drug: Regimen D
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D (injection gentamicin once daily for 2 days plus oral amoxicillin twice daily for 7 days)
Trial: 33720960
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (injection gentamicin once daily plus oral amoxicillin twice daily, both for 7 days)
Trial: 33720960
Drug: Regimen C
RxNorm normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C (once daily injection gentamicin plus injection procaine penicillin for 2 days, thereafter oral amoxicillin twice daily for 5 days)
Trial: 33720960
Drug: Regimen E
RxNorm normalized name: ASPIRIN 325 mg ORAL TABLET, COATED [Bayer Aspirin Regimen enteric coated]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen E (oral amoxicillin twice daily for 7 days)
Trial: 33720960
Drug: Reference regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference regimen A (injection gentamicin plus injection procaine penicillin both once daily for 7 days)
Trial: 32502358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard medication only)
Trial: 37310790
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks
Trial: 34814693
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections at the time of surgery
Trial: 33305552
Drug: Beta-alanine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (4.8 g·day-1 for four weeks)
Trial: 32268436
Drug: Early-onset abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-onset abiraterone acetate plus prednisone (AA+P) therapy
Trial: 32268436
Drug: Late-onset abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-onset abiraterone acetate plus prednisone (AA+P) therapy
Trial: 32268436
Drug: Missed early-onset
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed early-onset therapy assignment (MEC)
Trial: 32321565
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of chemotherapy (CT)
Trial: 32321565
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of chemotherapy followed by two cycles of durvalumab and subsequent maintenance treatment with durvalumab every 4 weeks
Trial: 32299371
Drug: Daily weight
RxNorm normalized name: Thrifty White One Daily Weight Control Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily weight monitoring
Trial: 34458922
Drug: Piperacillin/tazobactam therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam therapy
Trial: 34458922
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy on the day of reoperation
Trial: 34458922
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy on reoperation
Trial: 35730885
Drug: Carnoy's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnoy's solution (CS)
Trial: 33547717
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life (measured by Functional Assessment of Cancer Therapy-Palliative Care, range: 0-184)
Trial: 36348417
Drug: Conventional neurosurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neurosurgical treatment (control)
Trial: 33496811
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inhaled fluticasone propionate)
Trial: 32660260
Drug: EP test-guided
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP test-guided group (n=57) with adjunctive posterior wall isolation (PWI) performed in those with positive results (PWI subgroup; n=24)
Trial: 35303880
Drug: BMS-986020 (LPA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986020 (LPA1 antagonist)
Trial: 33125587
Drug: Treatment Ambassador
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Ambassador Program (TAP), an 8-session, peer-based, behavioral intervention
Trial: 33125587
Drug: Treatment Ambassador
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Ambassador Program (TAP)
Trial: 33962365
Drug: BF-FO (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF-FO (morning FO intake: DHA 1010 mg; EPA 240 mg; evening placebo: DHA 40 mg; EPA 15 mg)
Trial: 33962365
Drug: DN-FO (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DN-FO (evening FO intake: DHA 1010 mg; EPA 240 mg; morning placebo: DHA 40 mg; EPA 15 mg)
Trial: 36300550
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg tablet) from Glenmark
Trial: 36300550
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg tablet) from Citron
Trial: 36300550
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg tablet) from Harris
Trial: 36300550
Drug: Fasted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted treatment
Trial: 36300550
Drug: Fed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed treatment
Trial: 35302681
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing regimens of fremanezumab
Trial: 36115677
Drug: Diluted vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted vasopressin injection (20 units mixed with 100 mL normal saline)
Trial: 36115677
Drug: Diluted vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted vasopressin injection (20 units mixed with 200 mL normal saline)
Trial: 36115677
Drug: Diluted vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted vasopressin injection (20 units mixed with 400 mL normal saline)
Trial: 616401456
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 1200 mg of glutathione once a day for eight weeks
Trial: 616401456
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 0.4 g of inosine injection with 250 ml of 5% glucose once a day for eight weeks (Control)
Trial: 32222912
Drug: BC 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC 007 (15 mg, 50 mg, 150 mg)
Trial: 32222912
Drug: BC 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC 007 (150 mg)
Trial: 32222912
Drug: BC 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC 007 (50 mg, 150 mg)
Trial: 32222912
Drug: BC 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC 007 (300 mg, 450 mg, 750 mg, 1350 mg, 1900 mg)
Trial: 34473029
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with complete revascularization
Trial: 34473029
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical treatment with incomplete revascularization
Trial: 35734514
Drug: Thiamine mononitrate
RxNorm normalized name: Thiamine Mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine mononitrate 500 mg for 90 days
Trial: 34262398
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (TTG) for 4 weeks
Trial: 34262398
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (TTG) for 6 weeks
Trial: 32769596
Drug: Electromagnetic-focused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electromagnetic-focused extracorporeal shockwave treatment (F-ESWT) with energy flux density of 0.20 mJ/mm
Trial: 39250515
Drug: Resmetirom 80
RxNorm normalized name: resmetirom 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resmetirom 80 mg
Trial: 35745278
Drug: Two whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two whole eggs with 70 g of spinach/day (EGG)
Trial: 35978353
Drug: WeChat-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WeChat-based cognitive behavioral therapy intervention
Trial: 33209182
Drug: Proposed solutions
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed solutions for CBHI
Trial: 32968936
Drug: Routine symptomatic
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine symptomatic treatment (Control)
Trial: 34617959
Drug: Standard-dose heparins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose heparins
Trial: 34617959
Drug: Therapeutic-dose LMWH
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose LMWH (enoxaparin, 1 mg/kg subcutaneous, twice daily)
Trial: 34617959
Drug: Therapeutic-dose heparins
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose heparins
Trial: 34617959
Drug: Standard-dose heparins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose heparins (non-ICU)
Trial: 34617959
Drug: Therapeutic-dose heparins
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose heparins (non-ICU)
Trial: 34617959
Drug: Standard-dose heparins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose heparins (ICU)
Trial: 34617959
Drug: Therapeutic-dose heparins
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose heparins (ICU)
Trial: 32492084
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy in addition to standard treatment (n=52)
Trial: 32492084
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (control) (n=51)
Trial: 33316165
Drug: Activity trackers
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity trackers with 5 daily alarms
Trial: 35585556
Drug: Single-cycle intrathecal
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-cycle intrathecal therapy with two repeated injections of BM-MSCs (Lenzumestrocel) with a 26-day interval
Trial: 35585556
Drug: Single-cycle intrathecal
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-cycle intrathecal therapy with two repeated injections of BM-MSCs (Lenzumestrocel) with a 26-day interval + three additional booster injections at 4, 7, and 10 months
Trial: 33689236
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of furosemide
Trial: 33689236
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection (BI) of furosemide
Trial: 34053861
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg) plus carboplatin (AUC 5) plus pemetrexed (500 mg/m2)
Trial: 36007982
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec U100 (iDeg-100)
Trial: 34461080
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sildenafil citrate tablets
Trial: 33048344
Drug: Dose-dense weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-dense weekly paclitaxel with 3-weekly carboplatin
Trial: 32275352
Drug: Garcinia kola
RxNorm normalized name: GOTU KOLA
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garcinia kola (bitter kola) 100 mg/kg body weight in a 200 ml solution
Trial: 33138927
Drug: Outpatient motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient motivational enhancement therapy (MET, four sessions)
Trial: 34375501
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both exercises
Trial: 33432670
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for high-risk youth (FFT-HR)
Trial: 36455146
Drug: Anti-atherosclerotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-atherosclerotic treatments (Control)
Trial: 34408252
Drug: Urea +
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea + 5 Mg biochar ha-1 (B5)
Trial: 34408252
Drug: Urea +
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea + 10 Mg biochar ha-1 (B10)
Trial: 34408252
Drug: 5 Mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Mg biochar ha-1 (B5)
Trial: 34408252
Drug: 10 Mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Mg biochar ha-1 (B10)
Trial: 32065870
Drug: Trigone-including BTX-A
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Trigone-including BTX-A injection template